Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases

Abstract

Robust biomarkers for COPD may help direct patient-specific therapy, e.g. sputum eosinophilia in COPD patients predicts clinical response to ICS (Brightling C.E. et al. Thorax 2005:60:193-8). Peripheral blood eosinophil count has also been proposed as a biomarker to direct corticosteroid therapy during COPD exacerbations. We wished to quantify the extent to which ICS affected peripheral blood eosinophil count and conducted post-hoc analysis on two randomised, double-blind, placebo-controlled intervention studies in stable, steroid-naïve COPD subjects. RES106087 (NCT00379730) was a 6 wk study comparing placebo (n=44) with oral prednisolone (n=45) (Lomas D.A. et al. Eur Respir J 2009:34:95-102). SCO104925 (NCT00358358) was a 12 wk study comparing placebo (n=42), fluticasone propionate (FP)/salmeterol (SAL) 500/50mcg combination (n=39) and its individual components, FP 500mcg (n=42) and SAL 50mcg (n=38). As expected, oral prednisolone caused a mean reduction of 71 cells/microliter (SE 21.9) in blood eosinophils at 4 weeks that returned to baseline following washout. ICS caused a mean 55.3 cells/microliter (26.9) reduction at week 6 and a 34.2 cells/microliter (20.7) reduction at week 12. These data suggest there is minimal effect of ICS on blood eosinophil levels in COPD and that concurrent medication exclusions in phenotyping efforts should focus on oral corticosteroids.






Rating:

Share or cite this content

Citations should be made in the following way:
James Kreindler (Merion Station, United States of America), James Kreindler, Nicholas Locantore, Michael Watkins, Sally Lettis, Ruth Tal-Singer. Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients. Eur Respir J 2015; 46: Suppl. 59, 2959

Member's Comments

No comment yet.

Related content which might interest you: Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Relationship of blood eosinophil count to exacerbations in COPD Source: International Congress 2016 – Airway response to infection Year: 2016 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002 LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014